|
**Overview**: **SCA 4 Markers Profile****Introduction**: The SCA 4 Markers Profile is a diagnostic tool designed to screen for selected SCA markers using whole blood samples. Associated with conditions like spinocerebellar ataxia types 1-17 and related neurological disorders, these disorders present with coordination issues, ataxia, and severe complications if untreated, particularly in individuals with suspected neurological disorders. Per the 2023 Molecular Pathology guidelines, the test employs molecular pathology with PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for neurological disorder screening in clinical settings. This diagnostic falls under neurological disorder screening and targets individuals with suspected spinocerebellar ataxia, addressing the challenge of accurate genetic assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: SCA 4 Markers Pfl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by neurology labs, this test advanced targeted SCA screening.**Purpose**: The test screens for 16 parameters including SCA1 to guide ataxia assessment, assess selected genetic markers, and inform treatment and prevention strategies.**Test Parameters**: 1. SCA1, 2. SCA2, 3. SCA3, 4. SCA6, 5. ATXN1, 6. ATXN2, 7. ATXN3, 8. CACNA1A, 9. SCA7, 10. SCA12, 11. SCA17, 12. DRPLA, 13. ATXN7, 14. PPP2R2B, 15. TBP, 16. ATN1.**Pretest Condition**: No fasting required; patients should report coordination issues, ataxia, or recent neurological symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve DNA integrity.**Medical History**: Patients should provide details on coordination issues, ataxia, prior neurological reactions, or family history of ataxia, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated ataxia including neurological decline, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent blood transfusions can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible spinocerebellar ataxia, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in neurology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: MRI or genetic counseling for confirmation.**Test Limitations**: The test may produce false negatives in early stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Molecular Pathology Guidelines 2023, Journal of Neurology 2024, Biochemistry 2025. |
